FGF23 and disorders of phosphate homeostasis
- PMID: 15863037
- DOI: 10.1016/j.cytogfr.2005.01.002
FGF23 and disorders of phosphate homeostasis
Abstract
It is well known that fibroblast growth factor (FGF) family members are associated with embryonic development and are critical for basic metabolic functions. This review will focus upon fibroblast growth factor-23 (FGF23) and its roles in disorders associated with phosphate handling. The discovery that mutations in FGF23 were responsible for the isolated renal phosphate wasting disorder autosomal dominant hypophosphatemic rickets (ADHR) has ascribed novel functions to the FGF family. FGF23 circulates in the bloodstream, and animal models demonstrate that FGF23 controls phosphate and Vitamin D homeostasis through the regulation of specific renal proteins. The ADHR mutations in FGF23 produce a protein species less susceptible to proteolytic processing. X-linked hypophosphatemic rickets (XLH), tumor-induced osteomalacia (TIO), and fibrous dysplasia of bone (FD) are disorders involving phosphate homeostasis that share phenotypes with ADHR, indicating that FGF23 may be a common denominator for the pathophysiology of these syndromes. Our understanding of FGF23 will help to develop novel therapies for phosphate wasting disorders, as well as for disorders of increased serum phosphate, such as tumoral calcinosis, a rare disorder, and renal failure, a common disorder.
Similar articles
-
FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.Am J Physiol Endocrinol Metab. 2003 Jul;285(1):E1-9. doi: 10.1152/ajpendo.00016.2003. Am J Physiol Endocrinol Metab. 2003. PMID: 12791601 Review.
-
Fibroblast growth factor 23 and its receptors.Ther Apher Dial. 2005 Aug;9(4):308-12. doi: 10.1111/j.1744-9987.2005.00287.x. Ther Apher Dial. 2005. PMID: 16076372 Review.
-
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.Nat Genet. 2000 Nov;26(3):345-8. doi: 10.1038/81664. Nat Genet. 2000. PMID: 11062477
-
Emerging role of a phosphatonin in mineral homeostasis and its derangements.Eur J Clin Invest. 2006 Aug;36 Suppl 2:34-42. doi: 10.1111/j.1365-2362.2006.01659.x. Eur J Clin Invest. 2006. PMID: 16884396 Review.
-
Fibrous dysplasia, phosphate wasting and fibroblast growth factor 23.Pediatr Endocrinol Rev. 2007 Aug;4 Suppl 4:434-9. Pediatr Endocrinol Rev. 2007. PMID: 17982392 Review.
Cited by
-
The structural biology of the FGF19 subfamily.Adv Exp Med Biol. 2012;728:1-24. doi: 10.1007/978-1-4614-0887-1_1. Adv Exp Med Biol. 2012. PMID: 22396159 Free PMC article. Review.
-
betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c.Mol Endocrinol. 2008 Apr;22(4):1006-14. doi: 10.1210/me.2007-0313. Epub 2008 Jan 10. Mol Endocrinol. 2008. PMID: 18187602 Free PMC article.
-
Klotho and aging.Biochim Biophys Acta. 2009 Oct;1790(10):1049-58. doi: 10.1016/j.bbagen.2009.02.005. Epub 2009 Feb 20. Biochim Biophys Acta. 2009. PMID: 19230844 Free PMC article. Review.
-
Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model.FASEB J. 2009 Nov;23(11):3702-11. doi: 10.1096/fj.08-123992. Epub 2009 Jul 7. FASEB J. 2009. PMID: 19584304 Free PMC article.
-
Molecular bases of diseases characterized by hypophosphatemia and phosphaturia: new understanding.Clin Pediatr Endocrinol. 2006;15(4):129-35. doi: 10.1297/cpe.15.129. Epub 2006 Nov 3. Clin Pediatr Endocrinol. 2006. PMID: 24790333 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
